Hanmi Pharmaceuticals' MASH Candidate 'Efinopegdutide' Meets Primary Endpoint in Phase 2b Trial… Up to 63% MASH Resolution (Disclosed by MSD)
Efinopegdutide (MK-6024), a candidate treatment for metabolic dysfunction-associated steatohepatitis (MASH) developed by Hanmi Pharmaceuticals and licensed to U.S. pharmaceutical company MSD, met the primary efficacy endpoint in a phase 2b trial. In the 52-week trial, the proportion of patients who

Efinopegdutide (MK-6024), a candidate treatment for metabolic dysfunction-associated steatohepatitis (MASH) developed by Hanmi Pharmaceuticals and licensed to U.S. pharmaceutical company MSD, met the primary efficacy endpoint in a phase 2b trial. In the 52-week trial, the proportion of patients who met the criteria for MASH resolution without worsening of liver fibrosis was statistically significantly higher than in the placebo group. MSD disclosed the phase 2b results at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD) held in Denver, Colorado, on the 9th (local time), and the findings were also published in the international medical journal The Lancet.
[Trial design… 386 enrolled, 92% completed] The study was conducted in adult patients confirmed by liver biopsy to have MASH with F2 or F3 stage liver fibrosis. A total of 386 patients were enrolled, of whom 381 were randomized and received at least one dose of the study drug or comparator. Of all treated patients, 349 (92%) completed the trial. Researchers administered efinopegdutide at 4 mg, 7 mg, and 10 mg once weekly via subcutaneous injection and compared it with placebo, while a separate semaglutide 2.4 mg arm was also included.
[Primary endpoint of 'MASH resolution without worsening of liver fibrosis' met] After 52 weeks of treatment, the proportion meeting the primary endpoint of 'MASH resolution without worsening of liver fibrosis' was 56% in the efinopegdutide 4 mg group, 63% in the 7 mg group, and 61% in the 10 mg group, compared with only 13% in the placebo group. All three doses showed statistically significant differences versus placebo, with p-values below 0.0001 in each comparison. Here, MASH resolution means that the histological evaluation criteria defined in the trial were met; it does not mean that liver function fully returned to normal or that the disease was permanently cured.
[Liver fibrosis improvement… 7 mg group showed highest response rate, though optimal dose not yet determined] Dose-dependent differences were also observed in the key secondary evaluations related to liver fibrosis. The proportion of patients with at least one stage improvement in liver fibrosis without worsening of MASH was 43% in the 4 mg group, 52% in the 7 mg group, and 34% in the 10 mg group, compared with 21% in the placebo group. In this trial, the 7 mg group recorded the highest response rates in both MASH resolution and liver fibrosis improvement evaluations. However, these results alone do not confirm the optimal dosing level.
[Safety: Gastrointestinal adverse reactions… 10 mg group discontinuation rate draws attention] Gastrointestinal adverse reactions were observed in the safety evaluations. The incidence of nausea was 29% in the 4 mg group, 39% in the 7 mg group, and 44% in the 10 mg group, versus 11% in the placebo group. The rate of discontinuation of the study drug due to adverse reactions was 3% in the 4 mg group, 4% in the 7 mg group, and 11% in the 10 mg group, versus 1% in the placebo group. Notably, the 10 mg group showed a higher discontinuation rate due to adverse reactions than the other dose groups, indicating that both efficacy and safety should be considered together in future development.
[Dual action on GLP-1 and glucagon… FDA fast track designation] Efinopegdutide is a new drug candidate designed to act simultaneously on the GLP-1 receptor and the glucagon receptor. It is being developed by combining appetite and metabolic regulation through the GLP-1 receptor with energy expenditure and fat metabolism-related actions through the glucagon receptor. The U.S. Food and Drug Administration (FDA) has designated efinopegdutide for fast track status for the treatment of MASH. Fast track is a program designed to support the development and review of treatments for serious diseases, and it does not imply final approval of the drug's safety and efficacy or marketing authorization.
The development partnership between Hanmi Pharmaceuticals and MSD was also confirmed in the official announcement. MSD stated that efinopegdutide is being developed under an exclusive license agreement with Hanmi Pharmaceuticals.
[Remaining challenges: long-term effects and additional clinical confirmation needed] MASH is a disease in which fat accumulates in the liver, accompanied by inflammation and hepatocyte damage. As the disease progresses, liver fibrosis can worsen, and in some patients it can lead to cirrhosis or liver failure. This phase 2b trial is significant in that it evaluated the potential of efinopegdutide to resolve MASH and improve liver fibrosis. However, the currently disclosed results pertain to a 52-week treatment trial conducted in a specific patient population, and long-term efficacy and safety, as well as effectiveness in a broader patient population, must be confirmed through additional research. Meeting the primary endpoint in the phase 2b trial does not guarantee new drug approval, and subsequent clinical trials and regulatory review processes remain. Attention is focused on how these study results will carry forward in the future clinical development of efinopegdutide.
[Some AI assistance was used in producing this article. This article does not recommend buying or selling any specific stock, and investment decisions and responsibilities rest with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] U.S. October CPI Rises 0.4% Month-on-Month, Core CPI 0.3% — Markets Watch Fed's Rate Path](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F07%2F589065%2F626fecf2eac1716d%2Fvariants%2Fhero.webp&w=1920&q=75)
![[Seohak!Star] IonQ Named a Quantum Computing Market Leader by Gartner](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F07%2F588503%2F14b3af78be3af851%2Fvariants%2Fhero.webp&w=1920&q=75)
![[Seohak!Star] IonQ Partners with Carahsoft... Full-Scale Entry into U.S. Federal Government Quantum Technology Supply Chain](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F07%2F593384%2Ff0171ed8678444fd%2Fvariants%2Fhero.webp&w=1920&q=75)
